These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
80 related articles for article (PubMed ID: 2531784)
1. Augmentation of immune responses of pelvic lymph node lymphocytes in patients with cervical cancer by sizofiran. Shimizu Y; Chen JT; Hirai Y; Nakayama K; Hamada T; Fujimoto I; Hasumi K; Masubuchi K Nihon Sanka Fujinka Gakkai Zasshi; 1989 Dec; 41(12):2013-4. PubMed ID: 2531784 [No Abstract] [Full Text] [Related]
2. Augmenting effect of sizofiran on the immunofunction of regional lymph nodes in cervical cancer. Shimizu Y; Hasumi K; Masubuchi K Cancer; 1992 Mar; 69(5):1184-94. PubMed ID: 1739919 [TBL] [Abstract][Full Text] [Related]
3. Augmentative effect of lentinan on immune responses of pelvic lymph node lymphocytes in patients with uterine cervical cancer. Shimizu Y; Chen JT; Hirai Y; Shiokawa S; Yagi H; Katase K; Yamashiro T; Nakayama K; Teshima H; Hamada T Nihon Sanka Fujinka Gakkai Zasshi; 1988 Oct; 40(10):1557-8. PubMed ID: 3265714 [No Abstract] [Full Text] [Related]
4. In vivo interleukin 2-induced activation of lymphokine-activated killer cells and tumor cytotoxic T-cells in cervical lymph nodes of patients with head and neck tumors. Rivoltini L; Gambacorti-Passerini C; Squadrelli-Saraceno M; Grosso MI; Cantù G; Molinari R; Orazi A; Parmiani G Cancer Res; 1990 Sep; 50(17):5551-7. PubMed ID: 2386961 [TBL] [Abstract][Full Text] [Related]
5. [The characteristic of lymphokine-activated killer cells induced from tumor draining lymph-node cell]. Meng YG; Fu CY; Wang YZ Zhonghua Fu Chan Ke Za Zhi; 1994 Sep; 29(9):535-7, 574. PubMed ID: 7835130 [TBL] [Abstract][Full Text] [Related]
6. Effect of sizofiran on regional lymph nodes in patients with head and neck cancer. Kano Y; Kakuta H; Hashimoto J Biotherapy; 1996; 9(4):257-62. PubMed ID: 9012545 [TBL] [Abstract][Full Text] [Related]
7. [Augmentative effect of sizofiran on the immune functions of regional lymph nodes in patients with cervical cancer]. Shimizu Y; Teshima H; Chen JT; Fujimoto I; Hasumi K; Masubuchi K Nihon Sanka Fujinka Gakkai Zasshi; 1991 Jun; 43(6):581-8. PubMed ID: 1906916 [TBL] [Abstract][Full Text] [Related]
8. [Augmentation of cytotoxicity of regional lymph node lymphocytes of the stomach by in vitro culture in IL2 contained medium]. Akura Y; Tanaka N; Gotoh K; Kamitani S; Gangi J; Ono M; Yoshihara H; Ohida J; Orita K Nihon Gan Chiryo Gakkai Shi; 1986 Dec; 21(10):2411-20. PubMed ID: 3494799 [No Abstract] [Full Text] [Related]
9. Characterization of lymphokine-activated killer cells from peripheral blood and lymph nodes of non-Hodgkin's lymphoma patients. Nadkarni JJ; Jhaver KG; De AK; Soman CS; Nadkarni KS Neoplasma; 1993; 40(1):15-20. PubMed ID: 8350943 [TBL] [Abstract][Full Text] [Related]
10. Tumor-infiltrating lymphocytes contain higher numbers of type 1 cytokine expressors and DR+ T cells compared with lymphocytes from tumor draining lymph nodes and peripheral blood in patients with cancer of the uterine cervix. Santin AD; Ravaggi A; Bellone S; Pecorelli S; Cannon M; Parham GP; Hermonat PL Gynecol Oncol; 2001 Jun; 81(3):424-32. PubMed ID: 11371133 [TBL] [Abstract][Full Text] [Related]
11. Spermine-directed immunosuppression of cervical carcinoma cell sensitivity to a majority of lymphokine-activated killer lymphocyte cytotoxicity. Evans CH; Lee TS; Flugelman AA Nat Immun; 1995; 14(3):157-63. PubMed ID: 8832899 [TBL] [Abstract][Full Text] [Related]
12. Tumor-draining lymph nodes of primary lung cancer patients: a potent source of tumor-specific killer cells and dendritic cells. Kimura H; Dobrenkov K; Iida T; Suzuki M; Ando S; Yamamoto N Anticancer Res; 2005; 25(1A):85-94. PubMed ID: 15816523 [TBL] [Abstract][Full Text] [Related]
13. IL-12 and IL-2 potentiate the in vitro tumor-specific activity of peripheral blood cells from cervical cancer patients. Verma V; Sharma V; Shrivastava SK; Nadkarni JJ J Exp Clin Cancer Res; 2000 Sep; 19(3):367-74. PubMed ID: 11144531 [TBL] [Abstract][Full Text] [Related]
14. Lymphokine activated killer cells and interleukin-2 production in patients with cervical carcinoma. De AK; Jhaver KG; Kamat MR; Nadkarni JJ Neoplasma; 1991; 38(5):493-9. PubMed ID: 1835519 [TBL] [Abstract][Full Text] [Related]
15. Natural killer cell cytotoxicity in the peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Mickel RA; Kessler DJ; Taylor JM; Lichtenstein A Cancer Res; 1988 Sep; 48(17):5017-22. PubMed ID: 3409231 [TBL] [Abstract][Full Text] [Related]
16. Association between RCAS1 expression and microenvironmental immune cell death in uterine cervical cancer. Sonoda K; Miyamoto S; Hirakawa T; Yagi H; Yotsumoto F; Nakashima M; Watanabe T; Nakano H Gynecol Oncol; 2005 Jun; 97(3):772-9. PubMed ID: 15943986 [TBL] [Abstract][Full Text] [Related]
17. Induction of lymphokine-activated killer activities in peripheral blood lymphocytes and regional lymph node lymphocytes against PC-9 cultured adenocarcinoma and autologous pulmonary adenocarcinoma cells. Morikawa Y; Watanabe S; Kodama T Jpn J Clin Oncol; 1987 Jun; 17(2):129-39. PubMed ID: 3497285 [TBL] [Abstract][Full Text] [Related]
18. Cytokine-related immunomodulating activities of an anti-tumor glucan, sizofiran (SPG). Tsuchiya Y; Igarashi M; Inoue M; Kumagai K J Pharmacobiodyn; 1989 Oct; 12(10):616-25. PubMed ID: 2534316 [TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy changes the lymphocyte composition of tumor-draining lymph nodes in cervical carcinoma. Fattorossi A; Battaglia A; Ferrandina G; Coronetta F; Legge F; Salutari V; Scambia G Cancer; 2004 Apr; 100(7):1418-28. PubMed ID: 15042676 [TBL] [Abstract][Full Text] [Related]
20. Antiestrogens sensitize human ovarian and lung carcinomas for lysis by autologous killer cells. Baral E; Nagy E; Krepart GV; Lotocki RJ; Unruh HW; Berczi I Anticancer Res; 2000; 20(3B):2027-31. PubMed ID: 10928146 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]